AVEO

AVEO Pharmaceuticals, Inc. [AVEO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AVEO Stock Summary

In the News

10:32 29 Mar 2024 AVEO

4 Drug Stocks That More Than Doubled This Year

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

11:17 29 Mar 2024 AVEO

Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.

12:02 29 Mar 2024 AVEO

AVEO Oncology (AVEO): Strong Industry, Solid Earnings Estimate Revisions

AVEO Oncology (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

01:32 29 Mar 2024 AVEO

What Makes AVEO Pharmaceuticals (AVEO) a Strong Momentum Stock: Buy Now?

Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out.

08:19 29 Mar 2024 AVEO

AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

11:19 29 Mar 2024 AVEO

AVEO Pharmaceuticals (AVEO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

12:47 29 Mar 2024 AVEO

AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?

AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.

11:18 29 Mar 2024 AVEO

Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?

Here is how AVEO Pharmaceuticals (AVEO) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

07:32 29 Mar 2024 AVEO

Why LG Chem Is Buying AVEO Oncology (AVEO) For $566 Million

LG Chem is buying AVEO Oncology for $566 million. These are the details.

03:14 29 Mar 2024 AVEO

Biopharma Stock Soaring on Buyout News

Aveo Pharmaceuticals Inc (NASDAQ:AVEO) stock is soaring today, up 40.7% at $14.74 at last glance, after news that South Korean chemical company LG Chem plans to buy the biopharmaceutical name for $15 per share, or roughly $566 million, in an all-cash deal.

AVEO Financial details

Company Rating
Buy
Market Cap
0
Income
-40.52M
Revenue
90.9M
Book val./share
0.83
Cash/share
2.24
Dividend
-
Dividend %
-
Employees
114
Optionable
No
Shortable
Yes
Earnings
13 Mar 2023
P/E
-20.58
Forward P/E
-
PEG
6.97
P/S
-
P/B
18
P/C
6.7
P/FCF
-
Quick Ratio
2.29
Current Ratio
2.37
Debt / Equity
1.34
LT Debt / Equity
0.94
-
-
EPS (TTM)
-1.17
EPS next Y
-
EPS next Q
-
EPS this Y
72.29%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-14.17%
Revenue last 5Y
38.68%
Revenue Q/Q
20.33%
EPS Q/Q
-51.85%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-25%
ROE
-79%
ROC
-0.31%
Gross Margin
88%
Oper. Margin
-24%
Profit Margin
-33%
Payout
-
Shs Outstand
34.76M
Shs Float
34.34M
-
-
-
-
Target Price
14
52W Range
3.07-15.0
52W High
0%
52W Low
+400%
RSI
-
Rel Volume
0.43
Avg Volume
564.06K
Volume
245.3K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
-
-
-
Volatility
0%, 0%
Prev Close
0%
Price
15
Change
0.03%

AVEO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.720.411.870.281.82
Net income per share
-6.14-0.410.61-1.66-2.86
Operating cash flow per share
-1.81-1.91-0.19-1.77-2.68
Free cash flow per share
-1.81-1.91-0.19-1.79-2.68
Cash per share
3.161.873.112.894.08
Book value per share
-3.85-2.080.971.652.14
Tangible book value per share
-3.85-2.080.971.652.14
Share holders equity per share
-3.85-2.080.971.652.14
Interest debt per share
1.971.621.140.74-0.19
Market cap
295.54M209.17M95.99M123.49M100.38M
Enterprise value
317.65M203.78M81.97M75.87M29.84M
P/E ratio
-4.55-39.2510.23-3.47-1.64
Price to sales ratio
3938.673.3320.522.58
POCF ratio
-15.42-8.36-32.89-3.25-1.75
PFCF ratio
-15.42-8.36-32.89-3.22-1.75
P/B Ratio
-7.25-7.686.473.52.19
PTB ratio
-7.25-7.686.473.52.19
EV to sales
41.9137.672.8512.610.77
Enterprise value over EBITDA
-5.08-64.947.32-2.23-0.52
EV to operating cash flow
-16.58-8.14-28.08-2-0.52
EV to free cash flow
-16.58-8.14-28.08-1.98-0.52
Earnings yield
-0.22-0.030.1-0.29-0.61
Free cash flow yield
-0.06-0.12-0.03-0.31-0.57
Debt to equity
-0.45-0.71.060.40
Debt to assets
0.370.680.310.210
Net debt to EBITDA
-0.351.72-1.251.41.23
Current ratio
1.561.542.43.875.59
Interest coverage
-12.14-11.57-0.21-24.2212.25
Income quality
0.294.7-0.311.071.07
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.211.990.393.690
Research and developement to revenue
3.323.820.623.770.68
Intangibles to total assets
00000
Capex to operating cash flow
0000.010
Capex to revenue
000-0.060
Capex to depreciation
000-17.290
Stock based compensation to revenue
0.140.470.080.390.13
Graham number
23.054.373.647.8511.74
ROIC
1.293.09-0.01-0.88-1.24
Return on tangible assets
-1.3-0.190.19-0.53-0.58
Graham Net
-5.39-2.180.861.451.68
Working capital
18.06M9.82M29.48M48.56M86.01M
Tangible asset value
-40.76M-27.23M14.85M35.29M45.87M
Net current asset value
-40.78M-27.23M14.85M33.89M45.27M
Invested capital
-0.45-0.71.060.40
Average receivables
714.5K1.71M2.33M1.41M5.5M
Average payables
2.31M2.97M2.48M2.42M3.05M
Average inventory
0000828K
Days sales outstanding
19.36204.1920.6772.5992.12
Days payables outstanding
000990.92208.97
Days of inventory on hand
0000127.6
Receivables turnover
18.851.7917.655.033.96
Payables turnover
0000.371.75
Inventory turnover
00002.86
ROE
1.60.20.63-1.01-1.33
Capex per share
000-0.020

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.440.410.610.730.88
Net income per share
-0.3-0.44-0.33-0.27-0.13
Operating cash flow per share
-0.23-0.35-0.24-0.070.01
Free cash flow per share
-0.23-0.35-0.24-0.070.01
Cash per share
2.742.542.292.242.24
Book value per share
1.491.331.070.890.83
Tangible book value per share
1.491.331.070.890.83
Share holders equity per share
1.491.331.070.890.83
Interest debt per share
1.01-0.21.141.151.15
Market cap
212.43M161.26M192.72M226.34M284.91M
Enterprise value
177M90.73M157.07M194.61M246.19M
P/E ratio
-5.12-2.64-4.23-5.97-16.32
Price to sales ratio
1411.349.218.949.36
POCF ratio
-26.32-13.24-23.45-92.311.47K
PFCF ratio
-26.32-13.24-23.45-92.311.47K
P/B Ratio
4.153.525.227.49.88
PTB ratio
4.153.525.227.49.88
EV to sales
11.676.387.517.698.09
Enterprise value over EBITDA
-19.25-6.39-17.46-27.27-114.45
EV to operating cash flow
-21.93-7.45-19.11-79.371.27K
EV to free cash flow
-21.93-7.45-19.11-79.371.27K
Earnings yield
-0.05-0.09-0.06-0.04-0.02
Free cash flow yield
-0.04-0.08-0.04-0.010
Debt to equity
0.6501.031.261.34
Debt to assets
0.3100.390.390.38
Net debt to EBITDA
3.854.973.964.4518
Current ratio
4.835.594.813.12.37
Interest coverage
-7.990.89-7.59-6.14-1.97
Income quality
0.781.680.810.29-0.06
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.490.430.490.490.36
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
0.090.10.060.060.05
Graham number
3.183.652.822.341.54
ROIC
-0.11-0.28-0.13-0.12-0.04
Return on tangible assets
-0.1-0.15-0.12-0.1-0.04
Graham Net
1.281.050.840.650.59
Working capital
85.6M86.01M77.42M66.09M58.31M
Tangible asset value
51.23M45.87M36.94M30.59M28.85M
Net current asset value
50.12M45.27M36.45M30.06M28.34M
Invested capital
0.6501.031.261.34
Average receivables
7.55M9.66M11.79M14.95M17.95M
Average payables
4.04M3.82M2.86M3.31M4.32M
Average inventory
626K1.45M1.68M1.51M1.21M
Days sales outstanding
56.462.0759.2657.3758.42
Days payables outstanding
254.16120.06111.45105.86114.41
Days of inventory on hand
64.6173.3162.6438.7625.11
Receivables turnover
1.61.451.521.571.54
Payables turnover
0.350.750.810.850.79
Inventory turnover
1.391.231.442.323.58
ROE
-0.2-0.33-0.31-0.31-0.15
Capex per share
00000

AVEO Frequently Asked Questions

What is AVEO Pharmaceuticals, Inc. stock symbol ?

AVEO Pharmaceuticals, Inc. is a US stock , located in Boston of Ma and trading under the symbol AVEO

Is AVEO Pharmaceuticals, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $14. The lowest prediction is $14 and the highest is $14

What is AVEO stock prediction ?

What is AVEO Pharmaceuticals, Inc. stock quote today ?

AVEO Pharmaceuticals, Inc. stock price is $15 today.

Is AVEO Pharmaceuticals, Inc. stock public?

Yes, AVEO Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap